First in Human Study of Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 07 Feb 2019
Price : $35 *
At a glance
- Drugs Pioglitazone (Primary)
- Indications Pulmonary alveolar proteinosis
- Focus Adverse reactions; First in man
- Acronyms PioPAP
- 31 Jan 2019 Planned End Date changed from 1 Jul 2018 to 1 Jun 2020.
- 31 Jan 2019 Planned primary completion date changed from 1 Jul 2018 to 1 Jun 2019.
- 31 Jan 2019 Status changed from recruiting to active, no longer recruiting.